Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study
| Autor: | Vedat Hamuryudan, Fatma Nihan Akkoc-Mustafayev, Sinem Nihal Esatoglu, Yesim Ozguler, Ibrahim Hatemi, Aykut Ferhat Celik, Gulen Hatemi, Okan Kadir Nohut, Dilsen Cevirgen, Fatma Ozbakir, Hasan Yazici |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male Behç infliximab · Remicade immunogenicity Gastroenterology 0302 clinical medicine Immunology and Allergy Predict Original Research Rheumatoid-Arthritis biology Immunogenicity Behcet Syndrome Antibodies Anti-Idiotypic Rheumatoid arthritis Antirheumatic Agents drug level testing Female Antibody medicine.drug lcsh:Immunologic diseases. Allergy Adult medicine.medical_specialty Inflammatory Diseases Immunology Remicade Behçet disease 03 medical and health sciences Internal medicine medicine Humans Adverse effect 030203 arthritis & rheumatology Ankylosing spondylitis Inhibitors business.industry et disease drug antibodies medicine.disease Criteria Infliximab Rheumatology 030104 developmental biology infliximab · biology.protein Trough level business lcsh:RC581-607 |
| Zdroj: | Frontiers in Immunology Frontiers in Immunology, Vol 11 (2020) |
| ISSN: | 1664-3224 |
| Popis: | BackgroundImmunogenicity of tumor necrosis factor alpha inhibitors (TNFis) has been recognized as an important problem that may cause loss of efficacy and adverse events such as infusion reactions. TNFis are being increasingly used among patients with Behçet syndrome (BS) and scarce data exist on this topic.ObjectiveWe aimed to investigate the prevalence of anti-infliximab (IFX) antibodies in patients with Behçet syndrome together with suitable controls.MethodsWe collected serum samples from 66 consecutive Behçet syndrome patients (51 M, 15 F, mean age 37 ± 9 years) who were treated with IFX. Additionally, similarly treated 27 rheumatoid arthritis, 53 ankylosing spondylitis, 25 Crohn’s disease patients, and 31 healthy subjects were included as controls. Samples were collected just before an infusion, stored at −80°C until analysis, and serum IFX trough levels and anti-IFX antibodies were measured by ELISA. We used a cut-off value of 1 μg/ml for serum IFX trough level, extrapolating from rheumatoid arthritis studies.ResultsAnti-IFX antibodies were detected in four (6%) Behçet syndrome, five (18.5%) rheumatoid arthritis, three (12%) Crohn’s disease, and one (2%) ankylosing spondylitis patient. The median serum IFX trough level was significantly lower in patients with anti-IFX antibodies compared to those without antibodies [2.32 (IQR: 0.6–3.6) vs. 3.35 (IQR: 1.63–5.6); p = 0.019]. The serum IFX trough level was lower than the cut-off value in 6/13 (46%) patients with anti-IFX antibodies and in 25/158 (16%) patients without anti-IFX antibodies (p = 0.015). Among the four Behçet syndrome patients with anti-IFX antibodies, two experienced relapses and two had infusion reactions.ConclusionsImmunogenicity does not seem to be a frequent problem in Behçet syndrome patients treated with IFX, but may be associated with relapses and infusion reactions, when present. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|